Skip to main content
Fig. 3 | BMC Rheumatology

Fig. 3

From: Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study

Fig. 3

The change of the CT score after treatment initiation

(A) GGO score of the ABT group (n = 7). (B) Fibrosis score of the ABT group (n = 7). (C) GGO score of the JAKi group (n = 8). (D) Fibrosis score of the JAKi group (n = 8)

Change in the CT score. CT score was evaluated after treatment initiation. The median of the period between treatment initiation and the follow-up CT was 13 and 14.5 months for ABT and JAKi, respectively

GGO; grass ground opacity; CT: computer tomography; JAKi: Janus kinase inhibitor; ABT: abatacept

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us